IMAC Holdings, Inc. announced on May 23, 2024, Jeffrey S. Ervin notified the Board of his resignation as Chief Executive Officer, effective immediately. Mr. Ervin?s resignation not resulted from any disagreement with the Company?s operations, policies or practices. Effective May 24, 2024, Mr. Ervin and the Company entered into a Consulting Agreement pursuant to which Mr. Ervin will serve as an advisor to the Company to ensure a smooth management transition.

The Ervin Consulting Agreement has a term of four months and provides for Mr. Ervin to receive compensation consisting of eight thousand dollars per month. On May 23, 2024, the Company appointed Faith Zaslavsky as Chief Executive Officer of the Company, effective immediately. Ms. Zaslavsky, age 49, most recently served as Chief Executive Officer since June 2023, and President and Chief Operating Officer since December 2022, of Theralink Technologies, Inc. Prior to Theralink, Ms. Zaslavsky served as President of Oncology for Myriad Genetic Laboratories.

Her responsibilities included overseeing all commercial functions which include leading Medical Services, Medical Affairs, National and Enterprise Accounts and Sales and Marketing. She has spent 22 years leading and transforming teams, designing solutions for physicians to support care and advocating for patients facing a journey with cancer. She received a Business Administration degree from Washington State University.

Ms. Zaslavsky also serves on the board of directors of the American Society of Breast Surgeons Foundation.